Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
COVID-19, FLiRT
A small summer Covid wave may be ahead, experts say, as a new variant takes over
Disease experts anticipate a small uptick in Covid cases this summer, as a new variant spreads. The KP.2 variant represents 28% of Covid infections in the U.S., up from just 6% in mid-April, according to data released Friday by the Centers for Disease Control and Prevention.
There’s a New Covid Variant. What Will That Mean for Spring and Summer?
Experts are closely watching KP.2, now the leading variant. By Dani Blum For most of this year, the JN.1 variant of the coronavirus accounted for an overwhelming majority of Covid cases. But now, an offshoot variant called KP.
There’s a new, highly transmissible COVID-19 variant known as FLiRT
Despite their increased transmissibility, the new mutations don't appear to result in more severe disease. And the vaccine is expected to continue working well.
New COVID variant FLiRT has emerged. Here are the symptoms to watch for
Megan L. Ranney, dean of the Yale School of Public Health, told WebMD that FLiRT has some concerning features, like changes in the spike protein, which play a role in helping SARS-CoV-2 colonize the body and make people sick, USA TODAY reported.
There's a New Set of COVID Variants Called FLiRT: What You Need to Know
WEDNESDAY, May 8, 2024 (HealthDay News) -- The virus behind COVID has mutated again, this time producing variants nicknamed FLiRT, the U.S. Centers for Disease Control and Prevention (CDC) has reported.
There’s a new highly transmissible COVID-19 variant. Could FLiRT lead to a summer uptick?
In years past, summer travel and gatherings have spurred surges in coronavirus infections. As immunity wanes for those who received the most recent vaccine, experts urge caution.
"FLiRT" COVID variants are spreading. Scientists share what we know so far.
More than a third of COVID-19 cases in the U.S. are now estimated to be from a new, fast-growing member of a group of so-called "FLiRT" variants, nicknamed for their small but distinctive changes relative to the JN.
How dangerous is FLiRT? 5 things to know about new Covid-19 variant spreading in US
In the wake of waning immunity and social distancing no longer a norm, it's important to stay alert against the new Covid threat. Here're key facts about FLiRT.
FLiRT Covid variant: Everything we know so far about the coronavirus strain sweeping the US
Everything we know so far about the coronavirus strain sweeping the US - UKHSA data shows a rise in British cases of virus
New COVID ‘FLiRT’ variants show virus isn’t going away
CoV-2, the virus that causes COVID-19, are part of a group sometimes called “FLiRT” variants and serve as a reminder that the virus isn’t going away and
AstraZeneca, COVID-19 vaccine
AstraZeneca withdraws Covid-19 vaccine, citing low demand
AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand.
AstraZeneca pulls its COVID-19 vaccine from the European market
The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled.
Why AstraZeneca dey withdraw dia Covid vaccine afta more dan three billion doses
Afta more dan three billion doses, AstraZeneca don withdraw di Oxford-AstraZeneca Covid vaccine. AstraZeneca tok say dem dey "incredibly proud" of di vaccine, but dem don make commercial decision. Di organisation tok say di rise of new coronavirus variants mean say demand don shift go di newer updated vaccines.
Novavax, Sanofi and COVID-19 vaccine
Novavax shares double on Sanofi’s $1.4 billion investment for combo vaccine
The French pharmaceutical giant will work with Novavax to commercialize its existing COVI-19 vaccine and help develop a new combined vaccine for both COVID-19 and Influenza
Novavax Stock More Than Doubles On Deal With Sanofi To Co-commercialize Covid-19 Vaccine
Shares of American drug maker, Novavax, Inc. (NVAX), were surging in the pre-market trade on Friday after the company announced a
Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot.
1d
on MSN
Was COVID Vaccine Recalled Over Health Danger Fears? What We Know
AstraZeneca, which is withdrawing its COVID-19 vaccine, says independent estimates show that it saved over 6.5 million lives ...
MedPage Today on MSN
1d
Thousands of Kids Prescribed 'Potentially Harmful' Drugs for Acute COVID
Clinicians prescribed hydroxychloroquine (HCQ) and ivermectin inappropriately to thousands of children with acute COVID-19, ...
1d
on MSN
Mistrust, fights and blood sport: How COVID-19 trauma is shaping the 2024 election
Americans want to forget about COVID-19, but fallout from the pandemic is shaping voter attitudes about the nation's economy ...
12h
Covid Inquiry: CMO says his role was solely to advise ministers
Prof McBride, who has been in the role since 2006, told the inquiry that while he "wears two hats" - managing and advising - ...
12h
on MSN
Countries struggle to draft ‘pandemic treaty’ to avoid mistakes made during COVID
Countries are still struggling to come up with an agreed-upon plan for how the world might respond to the next global ...
1d
on MSN
Moderna’s mRNA dreams meet reality with first post-COVID shot
Moderna’s pioneering COVID shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its ...
17h
on MSN
Builder disqualified for abusing Covid loan scheme
A builder has been disqualified as a company director for 10 years after he falsely claimed a loan under the Covid Bounce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
United States
FLiRT
Novavax
AstraZeneca
Sanofi
Feedback